dr. fizazi on darolutamide-based therapy in nonmetastatic crpc
Published 5 years ago • 117 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:47
dr. fizazi discusses updated data with darolutamide in crpc
-
2:00
dr. shore on the tolerability of darolutamide in nonmetastatic crpc
-
1:46
examining the impact of darolutamide on pain and qol in patients with nonmetastatic crpc
-
0:54
the addition of darolutamide to adt reduces risk of metastasis in nonmetastatic crpc
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
2:14
dr. tagawa discusses darolutamide in crpc
-
6:51
understanding nonmetastatic crpc: an overview
-
2:58
achieving mfs and improved quality of life in nmcrpc with darolutamide
-
9:11
nubeqa medication: revolutionizing prostate cancer treatment for a better quality of life
-
10:55
treating high-risk gleason 8: a modern approach | mark scholz, md | pcri
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
2:02
assessing the role of darolutamide in crpc
-
5:12
darolutamide for nmcrpc: results of the aramis trial
-
0:20
darolutamide - nubeqa in a nutshell.
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
1:52
prostate cancer: quality of life maintained with darolutamide
-
2:11
dr. lee on the role of darolutamide in m0crpc
-
5:55
the future of treatment for nonmetastatic crpc
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
2:45
interaction of darolutamide with substrates of cyps and p-gp
-
2:46
aramis: darolutamide in patients with nmcrpc